

Special Issue

Structure and Cell Biology of Viral Infection

Message from the Guest Editor

To cover the latest update in the field of virology, we would like to invite you to submit your original research or review articles on fundamental structures within cell biology, as well as the advanced clinical studied on commercial drug development. The interesting areas for the specific Special Issue are 3D structural-based design together with cell-based technology for monoclonal antibody discovery, antiviral drugs, and vaccines to prevent viral infections and engineering viral vectors for gene and CAR-T cell therapy. We would like to cover various viruses such as: (1) coronavirus as the cause of the recent pandemic; (2) HIV/SIV as the most advanced research in the antiviral therapy and vaccine development; (3) adenovirus as viral vectors for vaccine and gene delivery; (4) lentiviral vectors as major tools for CAR-T cells in oncology; (5) AAV as the major delivery tool for gene therapy in rare diseases; and (6) other viruses or emerging viruses with implications for therapeutic development.

Guest Editor

Dr. Hung V. Trinh
Genezen, 9900 Westpoint Dr, Suite 128, Indianapolis, IN 46256, USA

Deadline for manuscript submissions

closed (31 August 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/117932

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).